Sort   by:  
 Page size 
Proteomics,MultiomicsAPOBEC3A is an Oral Cancer Prognostic Biomarker in Taiwanese Carriers of an APOBEC Deletion Polymorphism
Chen T-W, Lee C-C, Liu H, Wu C-S, Pickering CR, Huang P-J, et al., Nature Communications 8, Article number: 465 (2017) doi:10.1038/s41467-017-00493-9

Oral squamous cell carcinoma is a prominent cancer worldwide, p...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2019-08-28 | MSV000084250 | MassIVE
MetabolomicsELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to ...
2024-04-02 | MTBLS9418 | MetaboLights
UnknownA case of natural infection with Dirofilaria immitis in a coati (Nasua narica) from Mexico.
Not available
S-EPMC10251755 | biostudies-literature
UnknownMeasurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Not available
S-EPMC8906463 | biostudies-literature
UnknownLong-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
Not available
S-EPMC12550153 | biostudies-literature
TranscriptomicsTranscription profiling of human MDA-MB-231 cells response to adenovirus expressed estradiol-ERalpha, estradiol-Erbeta, and ERE Binding defective mutants
This SuperSeries is composed of the following subset Series:; GSE9757: Response to estradiol-ERalpha; GSE9758: Response to estradiol-ERalpha ERE Binding defective mutant; GSE9759: Response to estradiol-Erbeta and estradiol-ERbeta ERE binding defective mutant Experiment Overall Design: Refer to indiv...
ORGANISM(S): Homo sapiens 
2008-06-16 | E-GEOD-9761 | biostudies-arrayexpress
GenomicsChIP of BET proteins in iBET resistance [ChIP-seq]
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...
ORGANISM(S): Mus musculus 
2015-09-15 | E-GEOD-63682 | biostudies-arrayexpress
TranscriptomicsGenome wide expression analysis of BET inhibitor resistance
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluation ...
ORGANISM(S): Mus musculus 
2015-09-15 | E-GEOD-63575 | biostudies-arrayexpress
TranscriptomicsGenome wide expression analysis of BET inhibitor resistance [RNA-seq]
Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...
ORGANISM(S): Mus musculus 
2015-09-15 | E-GEOD-63681 | biostudies-arrayexpress
UnknownPhase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
Not available
S-EPMC7179282 | biostudies-literature
Sort   by:  
 Page size